Testosterone Enanthate and Tadalafil Interaction: Safety, Risks, and Clinical Guidance
Testosterone enanthate is an injectable, long-acting ester of testosterone used for FDA-approved testosterone replacement therapy (TRT) in men with hypogonadism. Tadalafil (brand name Cialis) is an oral phosphodiesterase type 5 (PDE5) inhibitor approved for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. The two drugs are frequently prescribed together in men's health clinics because low testosterone and erectile dysfunction often coexist, and treating one condition does not reliably resolve the other.
Direct answer: Testosterone enanthate and tadalafil do not share a meaningful pharmacokinetic interaction. Testosterone is not a clinically significant inhibitor or inducer of CYP3A4, the enzyme that metabolizes tadalafil, so neither drug is expected to change the other's blood levels at standard doses. No dose adjustment of either agent is required solely because the other is being used. The clinically relevant overlap is pharmacodynamic, not metabolic: both drugs affect vascular tone, and testosterone independently raises hematocrit, so the combination does not create a new pharmacokinetic hazard but does not reduce the need for the hematologic and cardiovascular monitoring that testosterone therapy already requires.
The question worth asking is not "do they conflict" but "does one drug mask the other's warning signs"
A generic interaction summary would stop at "no known interaction." That framing risks missing the actual clinical failure mode seen in combined TRT and PDE5-inhibitor prescribing: when tadalafil resolves the symptom that originally worried the patient (erectile difficulty), both patient and prescriber can lose the sense of urgency around labs that were ordered because of the testosterone, not the tadalafil. The interaction risk here is behavioral and monitoring-related, not molecular.
Why these two drugs end up prescribed together
Hypogonadism and erectile dysfunction share overlapping vascular and hormonal pathways, and testosterone therapy alone often produces only a partial improvement in erectile function. When erectile dysfunction persists after testosterone levels are normalized, adding a PDE5 inhibitor such as tadalafil is a standard next step in clinical practice. Trials in this area, including a hypogonadal-nonresponder study sometimes referred to as TADTEST, have reported that adding a PDE5 inhibitor produces larger improvements in erectile function scores than testosterone alone. The magnitude of that added benefit varies across studies, and readers should treat any specific point-estimate (for example, a stated mean IIEF-EF gain) as needing verification against the original trial report rather than as a fixed, universally reproducible number.
Pharmacokinetics: separate metabolic pathways
After intramuscular injection, testosterone enanthate is cleaved by plasma esterases to release free testosterone, which is then metabolized hepatically, primarily via CYP3A4-mediated pathways, with additional conversion to estradiol (via aromatase) and dihydrotestosterone (via 5-alpha reductase). Testosterone is not established as a clinically meaningful inhibitor or inducer of CYP3A4 at the concentrations produced by standard replacement dosing.
Tadalafil is a CYP3A4 substrate. Its prescribing information describes a long half-life (published as approximately 17.5 hours) and notes that strong CYP3A4 inhibitors, such as ketoconazole or ritonavir, substantially raise tadalafil exposure, which is why dose capping is recommended when those inhibitors are co-prescribed, per current tadalafil prescribing information. That interaction concern applies to strong CYP3A4 inhibitors generally, not to testosterone, which does not behave as a CYP3A4 inhibitor at replacement doses.
Neither drug is a recognized P-glycoprotein inhibitor at clinically relevant concentrations, so a transporter-mediated interaction is not expected. Taken together, the pharmacokinetic picture supports the conclusion that co-administration should not meaningfully change either drug's exposure. This is a plausibility-based conclusion built from mechanism and label data rather than from a dedicated testosterone-tadalafil pharmacokinetic interaction trial, and no such head-to-head PK study is cited here because one could not be verified for this draft.
Pharmacodynamic overlap: where monitoring actually matters
Blood pressure
Tadalafil causes mild vasodilation through nitric oxide/cGMP signaling; its label reports only small mean blood pressure reductions in healthy volunteers at the highest approved dose. Testosterone's effect on blood pressure is less predictable: some men experience modest reductions related to vascular effects, while others retain fluid and see blood pressure rise. Guideline bodies recommend checking blood pressure within the first several months of starting testosterone therapy specifically because of this fluid-retention effect. There is no published evidence of clinically significant hypotension from combining testosterone and tadalafil, but men also taking alpha-blockers or antihypertensives should have blood pressure checked, including standing readings, at follow-up visits.
Erythrocytosis
This is the highest-yield safety issue in the combination, and it belongs to testosterone, not tadalafil. Testosterone stimulates red blood cell production, and testosterone therapy is associated with a meaningfully higher rate of hematocrit elevation above the commonly used 54% threshold compared with placebo in randomized trial populations. Tadalafil has no known mechanism for raising hematocrit and does not worsen testosterone-induced erythrocytosis directly. The realistic risk is procedural: if tadalafil resolves the presenting complaint and the patient feels well, scheduled hematocrit checks tied to the testosterone prescription can get skipped. Endocrine Society guidance calls for a hematocrit check at baseline, again around 3 to 6 months after starting testosterone, and annually thereafter, with dose reduction or phlebotomy considered above 54%. Readers should verify the exact monitoring cadence against the current Endocrine Society guideline text rather than relying on a quoted excerpt, since the precise wording could not be confirmed against a verified source for this draft.
Cardiovascular risk
A large randomized cardiovascular safety trial of testosterone therapy in men with existing or elevated cardiovascular risk (widely referred to as the TRAVERSE trial, published in the New England Journal of Medicine in 2023) reported that testosterone did not increase major adverse cardiovascular events compared with placebo over the trial period. Tadalafil's cardiovascular safety profile across its approved indications has also not shown an excess of major adverse cardiovascular events in aggregate analyses cited in the tadalafil label and related literature. Neither of these findings comes from a trial that studied testosterone and tadalafil together, so the combined cardiovascular safety claim is an inference from two independent safety datasets, not a tested combination outcome. Anyone relying on the exact effect sizes from either trial should verify them against the primary publication before using them clinically.
Nitrate contraindication (tadalafil-specific, not testosterone-related)
The one absolute, FDA-labeled contraindication in this combination involves tadalafil alone. Tadalafil must not be given with any organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) because the combination can cause severe, potentially fatal hypotension. This is unrelated to testosterone. A man taking both testosterone enanthate and tadalafil who later needs nitrate therapy for angina, including in an emergency setting, must have the tadalafil accounted for; current tadalafil labeling recommends a waiting interval after the last tadalafil dose before nitrates are given in a medically necessary situation, and the exact interval should be confirmed against the current FDA label rather than assumed.
Dosing: no adjustment needed for either drug, but no individualized dosing here
No dose modification of testosterone enanthate is required because tadalafil is added, and no dose modification of tadalafil is required because testosterone enanthate is being used. Typical FDA-labeled dosing ranges are:
- Testosterone enanthate: individualized dosing per label, commonly in the range of 50 to 400 mg intramuscularly every 2 to 4 weeks for male hypogonadism, adjusted by a prescriber based on symptoms and lab trough levels.
- Tadalafil: as-needed dosing of 10 mg (adjustable between 5 and 20 mg) for erectile dysfunction, or 2.5 to 5 mg once daily for daily use or combined ED/BPH indications.
These ranges are general label information, not an individualized dosing recommendation. Actual dose selection, injection interval, and titration should be made by the prescribing clinician based on the individual patient's labs, symptoms, and comorbidities.
What a clinician or pharmacist should verify before signing off
Evidence-status interaction assessment
| Claim | Status | Basis | What still needs verification |
|---|---|---|---|
| No clinically significant CYP3A4 interaction between testosterone and tadalafil | Established / plausible | Testosterone is not a recognized CYP3A4 inhibitor at replacement doses; tadalafil label describes its CYP3A4 substrate status | No dedicated testosterone-tadalafil PK interaction trial identified; conclusion is mechanism-based |
| No dose adjustment needed for either drug when co-prescribed | Established by absence of a labeled interaction | FDA labeling for both agents does not list the other as an interacting drug | Confirm against the current label version at time of prescribing, since labels are periodically updated |
| Testosterone raises hematocrit and requires monitoring | Established | Testosterone's erythropoietic effect is well documented in randomized trial populations | Exact percentage of patients crossing the 54% threshold should be checked against the specific trial cited, not assumed from this article |
| Tadalafil does not raise hematocrit | Established (absence of mechanism and label signal) | No erythropoietic mechanism described for PDE5 inhibitors | None significant |
| Combination has no dedicated cardiovascular outcomes trial | Not established | TRAVERSE studied testosterone alone; tadalafil cardiovascular pooled data studied tadalafil alone | A combined-agent cardiovascular trial does not appear to exist; do not represent the combination as directly cardiovascular-outcome-tested |
| Tadalafil plus tadalafil-added benefit on erectile function over testosterone alone | Plausible, trial-suggested | Hypogonadal-nonresponder PDE5-inhibitor trials report added benefit | Specific effect sizes (mean IIEF-EF point changes) require verification against the primary trial report before being quoted as a precise number |
| Nitrate contraindication | Established, FDA label | Tadalafil label lists organic nitrates as an absolute contraindication | Confirm exact post-dose waiting interval against the current label |
| Additive hypotension risk with alpha-blockers/antihypertensives | Plausible, monitored in practice | Mechanistically additive vasodilation | No trial-level quantification of combined risk was located for this draft |
Evidence boundary
What is established: testosterone enanthate and tadalafil are metabolized through different primary pathways, neither drug is a recognized inhibitor of the other's clearance at standard doses, tadalafil's nitrate contraindication is absolute and unrelated to testosterone, and testosterone therapy independently requires hematocrit and blood pressure monitoring regardless of whether a PDE5 inhibitor is also prescribed.
What is plausible but not proven by a combination-specific trial: that adding tadalafil to testosterone therapy improves erectile function beyond testosterone alone (supported by hypogonadal-nonresponder studies, though exact effect sizes need primary-source verification), and that the cardiovascular safety of each drug studied independently extends to their combined use.
What is not established: there is no dedicated randomized trial evaluating cardiovascular outcomes, hematologic outcomes, or blood pressure outcomes of testosterone enanthate and tadalafil used together as a combination regimen. Safety conclusions about the combination are inferences from two separate evidence bases, not a tested pairing.
When to seek urgent care rather than wait for a routine follow-up
Chest pain, sudden vision loss, an erection lasting more than four hours, symptoms of a blood clot (leg swelling, unilateral pain, shortness of breath), or a known hematocrit above the threshold set by the prescriber are reasons to seek urgent evaluation rather than waiting for the next scheduled lab draw. Anyone taking tadalafil who is prescribed a nitrate in an emergency setting should tell the treating clinician about tadalafil use so nitrate timing can be adjusted appropriately.
Other interactions relevant to testosterone enanthate
Testosterone enanthate has recognized interactions independent of tadalafil that a prescriber should also track: it may increase the anticoagulant effect of warfarin, which can warrant closer INR monitoring; it can improve insulin sensitivity in men with type 2 diabetes, which may require adjustment of insulin or oral hypoglycemic doses to avoid hypoglycemia; and it can compound fluid retention when used with corticosteroids. Strong CYP3A4 inhibitors do not meaningfully affect testosterone but do raise tadalafil exposure and may require tadalafil dose capping per the tadalafil label.
References
Previous versions of this article referenced specific PubMed identifiers, precise efficacy measurements, and direct citations from Endocrine Society and AUA guidance regarding testosterone enanthate clinical evidence, including data from major studies. These references could not be validated against original research sources in the current review and have therefore been replaced with more general language. An editor with access to medical databases should verify the underlying studies before reintroducing specific numerical outcomes or verbatim guideline excerpts.